Publications

Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression.Salloum NC, Fava M, Hock RS, Freeman MP, Flynn M, Hoeppner B, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI. J Affect Disord. 2020 Jan 1; 2019 Sep 3. PMID: 31494365.
Lower synaptic density is associated with depression severity and network alterations.Holmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, DellaGioia N, Nabulsi N, Matuskey D, Angarita GA, Pietrzak RH, Duman RS, Sanacora G, Krystal JH, Carson RE, Esterlis I. Nat Commun. 2019 Apr 4; 2019 Apr 4. PMID: 30948709.
Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments.Duman RS, Sanacora G, Krystal JH. Neuron. 2019 Apr 3. PMID: 30946828.
Ketamine: A Paradigm Shift for Depression Research and Treatment.Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS. Neuron. 2019 Mar 6. PMID: 30844397.
Caution Against Overinterpreting Opiate Receptor Stimulation as Mediating Antidepressant Effects of Ketamine.Sanacora G. Am J Psychiatry. 2019 Mar 1. PMID: 30818992.
Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression.Salloum NC, Fava M, Freeman MP, Flynn M, Hoeppner B, Hock RS, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI. Depress Anxiety. 2019 Mar; 2018 Dec 30. PMID: 30597688.
Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression.Freeman MP, Papakostas GI, Hoeppner B, Mazzone E, Judge H, Cusin C, Mathew S, Sanacora G, Iosifescu D, DeBattista C, Trivedi MH, Fava M. J Psychiatr Res. 2019 Mar; 2019 Jan 8. PMID: 30641350.
ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol.Mathew SJ, Wilkinson ST, Altinay M, Asghar-Ali A, Chang LC, Collins KA, Dale RM, Hu B, Krishnan K, Kellner CH, Malone DA, Murrough JW, Ostroff RB, Sanacora G, Shao M, Anand A. Contemp Clin Trials. 2019 Feb; 2018 Dec 17. PMID: 30572160.
A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems.Wilkinson ST, Sanacora G. Drug Discov Today. 2019 Feb; 2018 Nov 14. PMID: 30447328.
Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Mol Psychiatry. 2019 Jan 7; 2019 Jan 7. PMID: 30617276.
The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development.Krystal AD, Pizzagalli DA, Mathew SJ, Sanacora G, Keefe R, Song A, Calabrese J, Goddard A, Goodman W, Lisanby SH, Smoski M, Weiner R, Iosifescu D, Nurnberger J Jr, Szabo S, Murrough J, Shekhar A, Potter W. Nat Rev Drug Discov. 2018 Dec 28. PMID: 30591715.
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Mol Psychiatry. 2018 Oct 3; 2018 Oct 3. PMID: 30283029.
The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?Abdallah CG, Sanacora G, Duman RS, Krystal JH. Pharmacol Ther. 2018 Oct; 2018 May 25. PMID: 29803629.
The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects.Abdallah CG, De Feyter HM, Averill LA, Jiang L, Averill CL, Chowdhury GMI, Purohit P, de Graaf RA, Esterlis I, Juchem C, Pittman BP, Krystal JH, Rothman DL, Sanacora G, Mason GF. Neuropsychopharmacology. 2018 Sep; 2018 Jun 28. PMID: 29977074.
Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital.Wilkinson ST, Katz RB, Toprak M, Webler R, Ostroff RB, Sanacora G. J Clin Psychiatry. 2018 Jul 24; 2018 Jul 24. PMID: 30063304.
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, Pinter C, Hough D, Sanacora G, Manji H, Drevets WC. Am J Psychiatry. 2018 Jul 1; 2018 Apr 16. PMID: 29656663.
Hopes and Skepticism for Unraveling the Unique Mechanisms of Ketamine's Rapid Onset Antidepressant Actions in Rodent Models.Sanacora G. Biol Psychiatry. 2018 Jul 1. PMID: 29929579.
Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [¹¹C]ABP688 and PET imaging study in depression.Esterlis I, DellaGioia N, Pietrzak RH, Matuskey D, Nabulsi N, Abdallah CG, Yang J, Pittenger C, Sanacora G, Krystal JH, Parsey RV, Carson RE, DeLorenzo C. Mol Psychiatry. 2018 Apr; 2017 Apr 11. PMID: 28397841.
Authorship Credit for Large Clinical Trials.Wilkinson ST, Sanacora G. JAMA. 2018 Feb 20. PMID: 29466586.
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA Jr, Sanacora G. Am J Psychiatry. 2018 Feb 1; 2017 Oct 3. PMID: 28969441.
Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale.van Schalkwyk GI, Wilkinson ST, Davidson L, Silverman WK, Sanacora G. J Affect Disord. 2018 Feb; 2017 Sep 28. PMID: 29045915.
Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD).Fava M, Freeman MP, Flynn M, Hoeppner BB, Shelton R, Iosifescu DV, Murrough JW, Mischoulon D, Cusin C, Rapaport M, Dunlop BW, Trivedi MH, Jha M, Sanacora G, Hermes G, Papakostas GI. Brain Stimul. 2018 Jan - Feb; 2017 Sep 23. PMID: 29030111.
Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: A letter to the editor.Katz RB, Toprak M, Wilkinson ST, Sanacora G, Ostroff R. Gen Hosp Psychiatry. 2018 Sep - Oct; 2018 May 22. PMID: 30100209.
A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.Mathew SJ, Gueorguieva R, Brandt C, Fava M, Sanacora G. Neuropsychopharmacology. 2017 Dec; 2017 May 29. PMID: 28553836.
Considerations on the Off-label Use of Ketamine as a Treatment for Mood Disorders.Wilkinson ST, Sanacora G. JAMA. 2017 Sep 5. PMID: 28806440.
Reply to: Ketamine and Psychosis History: Antidepressant Efficacy and Psychotomimetic Effects Postinfusion.Medeiros da Frota Ribeiro C, Sanacora G, Ostroff R. Biol Psychiatry. 2017 Sep 1; 2017 Jan 23. PMID: 28262251.
Co-occurring Catatonia and Posterior Reversible Encephalopathy Syndrome Responsive to Electroconvulsive Therapy.Klingensmith KE, Sanacora G, Ostroff R. J ECT. 2017 Sep. PMID: 28383349.
Ketamine for the Treatment of Depression-Reply.Sanacora G. JAMA Psychiatry. 2017 Sep 1. PMID: 28700772.
Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic.Krystal JH, Abdallah CG, Averill LA, Kelmendi B, Harpaz-Rotem I, Sanacora G, Southwick SM, Duman RS. Curr Psychiatry Rep. 2017 Aug 26; 2017 Aug 26. PMID: 28844076.
A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders.Wilkinson ST, Toprak M, Turner MS, Levine SP, Katz RB, Sanacora G. Am J Psychiatry. 2017 Jul 1. PMID: 28669202.
Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study.Abdallah CG, Hannestad J, Mason GF, Holmes SE, DellaGioia N, Sanacora G, Jiang L, Matuskey D, Satodiya R, Gasparini F, Lin X, Javitch J, Planeta B, Nabulsi N, Carson RE, Esterlis I. Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Jul; 2017 Apr 6. PMID: 28993818.
Hippocampal volume changes following electroconvulsive therapy: a systematic review and meta-analysis.Wilkinson ST, Sanacora G, Bloch MH. Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 May; 2017 Feb 5. PMID: 28989984.
Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders.Sanacora G, Heimer H, Hartman D, Mathew SJ, Frye M, Nemeroff C, Robinson Beale R. Neuropsychopharmacology. 2017 May; 2016 Sep 19. PMID: 27640324.
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB. JAMA Psychiatry. 2017 Apr 1. PMID: 28249076.
Computer-Assisted Cognitive Behavior Therapy to Prevent Relapse Following Electroconvulsive Therapy.Wilkinson ST, Ostroff RB, Sanacora G. J ECT. 2017 Mar. PMID: 27564424.
Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study.Sanacora G, Johnson MR, Khan A, Atkinson SD, Riesenberg RR, Schronen JP, Burke MA, Zajecka JM, Barra L, Su HL, Posener JA, Bui KH, Quirk MC, Piser TM, Mathew SJ, Pathak S. Neuropsychopharmacology. 2017 Mar; 2016 Sep 29. PMID: 27681442.
Characterization of GABAergic marker expression in the chronic unpredictable stress model of depression.Banasr M, Lepack A, Fee C, Duric V, Maldonado-Aviles J, DiLeone R, Sibille E, Duman RS, Sanacora G. Chronic Stress (Thousand Oaks). 2017 Feb; 2017 Aug 3. PMID: 28835932.
Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects.Chowdhury GM, Zhang J, Thomas M, Banasr M, Ma X, Pittman B, Bristow L, Schaeffer E, Duman RS, Rothman DL, Behar KL, Sanacora G. Mol Psychiatry. 2017 Jan; 2016 Apr 12. PMID: 27067013.
Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders.Haroon E, Miller AH, Sanacora G. Neuropsychopharmacology. 2017 Jan; 2016 Sep 15. PMID: 27629368.
Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression.Wilkinson ST, Wright D, Fasula MK, Fenton L, Griepp M, Ostroff RB, Sanacora G. Psychother Psychosom. 2017; 2017 May 11. PMID: 28490030.
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, Pinter C, Murrough JW, Sanacora G, Shelton RC, Kurian B, Winokur A, Fava M, Manji H, Drevets WC, Van Nueten L. Am J Psychiatry. 2016 Aug 1; 2016 Apr 8. PMID: 27056608.
KETAMINE: A POTENTIAL RAPID-ACTING ANTISUICIDAL AGENT?Wilkinson ST, Sanacora G. Depress Anxiety. 2016 Aug; 2016 Apr 15. PMID: 27082101.
KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.Abdallah CG, Adams TG, Kelmendi B, Esterlis I, Sanacora G, Krystal JH. Depress Anxiety. 2016 Aug; 2016 Apr 6. PMID: 27062302.
Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research.Krystal JH, Abi-Dargham A, Akbarian S, Arnsten AFT, Barch DM, Bearden CE, Braff DL, Brown ES, Bullmore ET, Carlezon WA Jr, Carter CS, Cook EH Jr, Daskalakis ZJ, DiLeone RJ, Duman RS, Grace AA, Hariri AR, Harrison PJ, Hiroi N, Kenny PJ, Kleinman JE, Krystal AD, Lewis DA, Lipska BK, Marder SR, Mason GF, Mathalon DH, McClung CA, McDougle CJ, McIntosh AM, McMahon FJ, Mirnics K, Monteggia LM, Narendran R, Nestler EJ, Neumeister A, O'Donovan MC, Öngür D, Pariante CM, Paulus MP, Pearlson G, Phillips ML, Pine DS, Pizzagalli DA, Pletnikov MV, Ragland JD, Rapoport JL, Ressler KJ, Russo SJ, Sanacora G, Sawa A, Schatzberg AF, Shaham Y, Shamay-Tsoory SG, Sklar P, State MW, Stein MB, Strakowski SM, Taylor SF, Turecki G, Turetsky BI, Weissman MM, Zachariou V, Zarate CA Jr, Zubieta JK. Biol Psychiatry. 2016 Jul 15. PMID: 27346079.
What Are We Learning From Early-Phase Clinical Trials With Glutamate Targeting Medications for the Treatment of Major Depressive Disorder.Sanacora G. JAMA Psychiatry. 2016 Jul 1. PMID: 27303925.
The Use of Ketamine for the Treatment of Depression in the Context of Psychotic Symptoms: To the Editor.da Frota Ribeiro CM, Sanacora G, Hoffman R, Ostroff R. Biol Psychiatry. 2016 May 1; 2015 Jun 4. PMID: 26212896.
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Nat Med. 2016 Mar. PMID: 26937618.
A history of early life parental loss or separation is associated with successful cognitive-behavioral therapy in major depressive disorder.Niciu MJ, Abdallah CG, Fenton LR, Fasula MK, Black A, Anderson GM, Sanacora G. J Affect Disord. 2015 Nov 15; 2015 Aug 19. PMID: 26363143.
Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial.Pittenger C, Bloch MH, Wasylink S, Billingslea E, Simpson R, Jakubovski E, Kelmendi B, Sanacora G, Coric V. J Clin Psychiatry. 2015 Aug. PMID: 26214725.
Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?Sanacora G, Schatzberg AF. Neuropsychopharmacology. 2015 Mar 13; 2015 Mar 13. PMID: 25767082.
In vivo ketamine-induced changes in [¹¹C]ABP688 binding to metabotropic glutamate receptor subtype 5.DeLorenzo C, DellaGioia N, Bloch M, Sanacora G, Nabulsi N, Abdallah C, Yang J, Wen R, Mann JJ, Krystal JH, Parsey RV, Carson RE, Esterlis I. Biol Psychiatry. 2015 Feb 1; 2014 Jul 10. PMID: 25156701.
Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.Abdallah CG, Sanacora G, Duman RS, Krystal JH. Annu Rev Med. 2015; 2014 Oct 17. PMID: 25341010.
Regulation of extrasynaptic glutamate levels as a pathophysiological mechanism in disorders of motivation and addiction.McCullumsmith RE, Sanacora G. Neuropsychopharmacology. 2015 Jan. PMID: 25482181.
Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?Sanacora G, Schatzberg AF. Neuropsychopharmacology. 2015 Jan; 2014 Sep 26. PMID: 25257213.
Glutamate metabolism in major depressive disorder.Abdallah CG, Jiang L, De Feyter HM, Fasula M, Krystal JH, Rothman DL, Mason GF, Sanacora G. Am J Psychiatry. 2014 Dec 1; 2014 Oct 31. PMID: 25073688.
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ, Quirk MC. Mol Psychiatry. 2014 Sep; 2013 Oct 15. PMID: 24126931.
Decreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder.Abdallah CG, Niciu MJ, Fenton LR, Fasula MK, Jiang L, Black A, Rothman DL, Mason GF, Sanacora G. Psychother Psychosom. 2014; 2014 Aug 6. PMID: 25116726.
Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?Niciu MJ, Henter ID, Sanacora G, Zarate CA Jr. World J Biol Psychiatry. 2014 Jan; 2013 Sep 12. PMID: 24024876.
Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses.Voleti B, Navarria A, Liu RJ, Banasr M, Li N, Terwilliger R, Sanacora G, Eid T, Aghajanian G, Duman RS. Biol Psychiatry. 2013 Nov 15; 2013 Jun 14. PMID: 23751205.
Delayed amnesic syndrome after riluzole use in major depressive disorder: a case report.Cardoos A, Inamori A, Sanacora G, Fava M, Mischoulon D. Psychosomatics. 2013 Sep-Oct; 2013 Mar 6. PMID: 23473447.
From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders.Sanacora G, Banasr M. Biol Psychiatry. 2013 Jun 15. PMID: 23726152.
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.Krystal JH, Sanacora G, Duman RS. Biol Psychiatry. 2013 Jun 15. PMID: 23726151.
Effects of ketamine in treatment-refractory obsessive-compulsive disorder.Bloch MH, Wasylink S, Landeros-Weisenberger A, Panza KE, Billingslea E, Leckman JF, Krystal JH, Bhagwagar Z, Sanacora G, Pittenger C. Biol Psychiatry. 2012 Dec 1; 2012 Jul 10. PMID: 22784486.
Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients.Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N, Kelmendi B, Simen A, McMahon FJ, Sanacora G, Zarate C Jr. Biol Psychiatry. 2012 Dec 1; 2012 Jul 6. PMID: 22771240.
Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting.Abdallah CG, Fasula M, Kelmendi B, Sanacora G, Ostroff R. J ECT. 2012 Sep. PMID: 22847373.
¹H-[¹³C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism.Chowdhury GM, Behar KL, Cho W, Thomas MA, Rothman DL, Sanacora G. Biol Psychiatry. 2012 Jun 1; 2011 Dec 9. PMID: 22169441.
Cortical GABA levels in primary insomnia.Morgan PT, Pace-Schott EF, Mason GF, Forselius E, Fasula M, Valentine GW, Sanacora G. Sleep. 2012 Jun 1; 2012 Jun 1. PMID: 22654200.
Glutamate-based depression GBD.McCarthy DJ, Alexander R, Smith MA, Pathak S, Kanes S, Lee CM, Sanacora G. Med Hypotheses. 2012 May; 2012 Mar 4. PMID: 22391030.
Intravenous ethanol infusion decreases human cortical γ-aminobutyric acid and N-acetylaspartate as measured with proton magnetic resonance spectroscopy at 4 tesla.Gomez R, Behar KL, Watzl J, Weinzimer SA, Gulanski B, Sanacora G, Koretski J, Guidone E, Jiang L, Petrakis IL, Pittman B, Krystal JH, Mason GF. Biol Psychiatry. 2012 Feb 1; 2011 Aug 19. PMID: 21855054.
The roles of glutamate receptors across major neurological and psychiatric disorders.Siegel S, Sanacora G. Pharmacol Biochem Behav. 2012 Feb; 2011 Nov 13. PMID: 22108650.
Overview of glutamatergic neurotransmission in the nervous system.Niciu MJ, Kelmendi B, Sanacora G. Pharmacol Biochem Behav. 2012 Feb; 2011 Aug 26. PMID: 21889952.
Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice.Gourley SL, Espitia JW, Sanacora G, Taylor JR. Psychopharmacology (Berl). 2012 Feb; 2011 Jul 21. PMID: 21779782.
Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.Sanacora G, Treccani G, Popoli M. Neuropharmacology. 2012 Jan; 2011 Aug 3. PMID: 21827775.
The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission.Popoli M, Yan Z, McEwen BS, Sanacora G. Nat Rev Neurosci. 2011 Nov 30; 2011 Nov 30. PMID: 22127301.
Association of polymorphisms in HCN4 with mood disorders and obsessive compulsive disorder.Kelmendi B, Holsbach-Beltrame M, McIntosh AM, Hilt L, George ED, Kitchen RR, Carlyle BC, Pittenger C, Coric V, Nolen-Hoeksema S, Sanacora G, Simen AA. Neurosci Lett. 2011 Jun 8; 2011 Apr 20. PMID: 21529705.
Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial.Saricicek A, Maloney K, Muralidharan A, Ruf B, Blumberg HP, Sanacora G, Lorberg B, Pittman B, Bhagwagar Z. J Clin Psychiatry. 2011 Jun; 2010 Oct 19. PMID: 21034692.
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, Krystal JH, Sanacora G. Psychiatry Res. 2011 Feb 28; 2011 Jan 12. PMID: 21232924.
Computerized ambulatory monitoring in mood disorders: feasibility, compliance, and reactivity.Husky MM, Gindre C, Mazure CM, Brebant C, Nolen-Hoeksema S, Sanacora G, Swendsen J. Psychiatry Res. 2010 Jul 30; 2010 May 21. PMID: 20488558.
Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole.Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, Sanacora G. Mol Psychiatry. 2010 May; 2008 Sep 30. PMID: 18825147.
Cortical inhibition, gamma-aminobutyric acid, and major depression: there is plenty of smoke but is there fire?Sanacora G. Biol Psychiatry. 2010 Mar 1. PMID: 20159143.
Reduced density of calbindin immunoreactive GABAergic neurons in the occipital cortex in major depression: relevance to neuroimaging studies.Maciag D, Hughes J, O'Dwyer G, Pride Y, Stockmeier CA, Sanacora G, Rajkowska G. Biol Psychiatry. 2010 Mar 1; 2009 Dec 9. PMID: 20004363.
Do glutamatergic agents represent a new class of antidepressant drugs? Part 2.Sanacora G. J Clin Psychiatry. 2009 Nov. PMID: 20031105.
Do glutamatergic agents represent a new class of antidepressant drugs? Part 1.Sanacora G. J Clin Psychiatry. 2009 Oct. PMID: 19906350.
Targeting glial physiology and glutamate cycling in the treatment of depression.Valentine GW, Sanacora G. Biochem Pharmacol. 2009 Sep 1; 2009 Apr 17. PMID: 19376090.
Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia.Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, Hoffman RE, D'Souza DC. Drug Discov Today. 2009 Jul; 2009 May 19. PMID: 19460458.
Reviewing medications for bipolar disorder: understanding the mechanisms of action.Sanacora G. J Clin Psychiatry. 2009 Jan. PMID: 19222977.
Chronic riluzole treatment increases glucose metabolism in rat prefrontal cortex and hippocampus.Chowdhury GM, Banasr M, de Graaf RA, Rothman DL, Behar KL, Sanacora G. J Cereb Blood Flow Metab. 2008 Dec; 2008 Jul 16. PMID: 18628780.
Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications.Sen S, Duman R, Sanacora G. Biol Psychiatry. 2008 Sep 15; 2008 Jun 24. PMID: 18571629.
Major depression: emerging therapeutics.Sen S, Sanacora G. Mt Sinai J Med. 2008 May-Jun. PMID: 18704976.
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.Sanacora G, Zarate CA, Krystal JH, Manji HK. Nat Rev Drug Discov. 2008 May. PMID: 18425072.
It is time to take a stand for medical research and against terrorism targeting medical scientists.Krystal JH, Carter CS, Geschwind D, Manji HK, March JS, Nestler EJ, Zubieta JK, Charney DS, Goldman D, Gur RE, Lieberman JA, Roy-Byrne P, Rubinow DR, Anderson SA, Barondes S, Berman KF, Blair J, Braff DL, Brown ES, Calabrese JR, Carlezon WA Jr, Cook EH Jr, Davidson RJ, Davis M, Desimone R, Drevets WC, Duman RS, Essock SM, Faraone SV, Freedman R, Friston KJ, Gelernter J, Geller B, Gill M, Gould E, Grace AA, Grillon C, Gueorguieva R, Hariri AR, Innis RB, Jones EG, Kleinman JE, Koob GF, Krystal AD, Leibenluft E, Levinson DF, Levitt PR, Lewis DA, Liberzon I, Lipska BK, Marder SR, Markou A, Mason GF, McDougle CJ, McEwen BS, McMahon FJ, Meaney MJ, Meltzer HY, Merikangas KR, Meyer-Lindenberg A, Mirnics K, Monteggia LM, Neumeister A, O'Brien CP, Owen MJ, Pine DS, Rapoport JL, Rauch SL, Robbins TW, Rosenbaum JF, Rosenberg DR, Ross CA, Rush AJ, Sackeim HA, Sanacora G, Schatzberg AF, Shaham Y, Siever LJ, Sunderland T, Tecott LH, Thase ME, Todd RD, Weissman MM, Yehuda R, Yoshikawa T, Young EA, McCandless R. Biol Psychiatry. 2008 Apr 15. PMID: 18371494.
Riluzole in the treatment of mood and anxiety disorders.Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G. CNS Drugs. 2008. PMID: 18698875.
New understanding of mechanisms of action of bipolar medications.Sanacora G. J Clin Psychiatry. 2008. PMID: 19265637.
GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action.Sanacora G, Saricicek A. CNS Neurol Disord Drug Targets. 2007 Apr. PMID: 17430150.
The NMDA receptor as a therapeutic target in major depressive disorder.Pittenger C, Sanacora G, Krystal JH. CNS Neurol Disord Drug Targets. 2007 Apr. PMID: 17430148.
Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms.Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, Krystal JH. Biol Psychiatry. 2007 Mar 15; 2006 Dec 4. PMID: 17141740.
Antidepressant-like effects of ceftriaxone in male C57BL/6J mice.Mineur YS, Picciotto MR, Sanacora G. Biol Psychiatry. 2007 Jan 15; 2006 Jul 24. PMID: 16860779.
Can cognitive behavioral therapy reduce relapse rates of depression after ECT? a preliminary study.Fenton L, Fasula M, Ostroff R, Sanacora G. J ECT. 2006 Sep. PMID: 16957536.
Joint analysis of repeatedly observed continuous and ordinal measures of disease severity.Gueorguieva RV, Sanacora G. Stat Med. 2006 Apr 30. PMID: 16217846.
Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression.Geracioti TD Jr, Carpenter LL, Owens MJ, Baker DG, Ekhator NN, Horn PS, Strawn JR, Sanacora G, Kinkead B, Price LH, Nemeroff CB. Am J Psychiatry. 2006 Apr. PMID: 16585438.

Publications

Longer-term open-label study of adjunctive riluzole in treatment-resistant depression.Sakurai H, Dording C, Yeung A, Foster S, Jain F, Chang T, Trinh NH, Bernard R, Boyden S, Iqbal SZ, Wilkinson ST, Mathew SJ, Mischoulon D, Fava M, Cusin C. J Affect Disord. 2019 Nov 1; 2019 Jul 2. PMID: 31400624.
Associations of Adverse Childhood Experiences with Past-Year DSM-5 Psychiatric and Substance Use Disorders in Older Adults.Rhee TG, Barry LC, Kuchel GA, Steffens DC, Wilkinson ST. J Am Geriatr Soc. 2019 Oct; 2019 Jun 17. PMID: 31206597.
Psychiatric Practice Patterns and Barriers to the Adoption of Esketamine.Wilkinson ST, Howard DH, Busch SH. JAMA. 2019 Aug 2; 2019 Aug 2. PMID: 31373610.
A Measure to Assess Perceptions and Knowledge About Electroconvulsive Therapy: Development and Psychometric Properties.Tsai J, Huang M, Wilkinson ST, Edelen C, Rosenheck RA, Holtzheimer PE. J ECT. 2019 Jun 11; 2019 Jun 11. PMID: 31192871.
Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant.Wilkinson ST, Farmer C, Ballard ED, Mathew SJ, Grunebaum MF, Murrough JW, Sos P, Wang G, Gueorguieva R, Zarate CA Jr. Neuropsychopharmacology. 2019 Jun; 2019 Jan 17. PMID: 30653192.
Leveraging Neuroplasticity to Enhance Adaptive Learning: The Potential for Synergistic Somatic-Behavioral Treatment Combinations to Improve Clinical Outcomes in Depression.Wilkinson ST, Holtzheimer PE, Gao S, Kirwin DS, Price RB. Biol Psychiatry. 2019 Mar 15; 2018 Sep 20. PMID: 30528745.
The Successful Use of Electroconvulsive Therapy in a Patient With Cerebral Aneurysms and a Pituitary Lesion.Kitay BM, Katz RB, Wilkinson ST, Ostroff RB. J ECT. 2019 Mar. PMID: 29952859.
Access to Outpatient Electroconvulsive Therapy at VA Medical Centers - Reply.Wilkinson ST, Rosenheck R. J ECT. 2019 Mar. PMID: 29901498.
ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol.Mathew SJ, Wilkinson ST, Altinay M, Asghar-Ali A, Chang LC, Collins KA, Dale RM, Hu B, Krishnan K, Kellner CH, Malone DA, Murrough JW, Ostroff RB, Sanacora G, Shao M, Anand A. Contemp Clin Trials. 2019 Feb; 2018 Dec 17. PMID: 30572160.
A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems.Wilkinson ST, Sanacora G. Drug Discov Today. 2019 Feb; 2018 Nov 14. PMID: 30447328.
Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Mol Psychiatry. 2019 Jan 7; 2019 Jan 7. PMID: 30617276.
Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression.Wilkinson ST, Kiselycznyk C, Banasr M, Webler RD, Haile C, Mathew SJ. J Affect Disord. 2018 Dec 1; 2018 Aug 18. PMID: 30153634.
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Mol Psychiatry. 2018 Oct 3; 2018 Oct 3. PMID: 30283029.
Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital.Wilkinson ST, Katz RB, Toprak M, Webler R, Ostroff RB, Sanacora G. J Clin Psychiatry. 2018 Jul 24; 2018 Jul 24. PMID: 30063304.
Identifying Recipients of Electroconvulsive Therapy: Data From Privately Insured Americans.Wilkinson ST, Agbese E, Leslie DL, Rosenheck RA. Psychiatr Serv. 2018 May 1; 2018 Feb 1. PMID: 29385954.
Authorship Credit for Large Clinical Trials.Wilkinson ST, Sanacora G. JAMA. 2018 Feb 20. PMID: 29466586.
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA Jr, Sanacora G. Am J Psychiatry. 2018 Feb 1; 2017 Oct 3. PMID: 28969441.
Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale.van Schalkwyk GI, Wilkinson ST, Davidson L, Silverman WK, Sanacora G. J Affect Disord. 2018 Feb; 2017 Sep 28. PMID: 29045915.
Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: A letter to the editor.Katz RB, Toprak M, Wilkinson ST, Sanacora G, Ostroff R. Gen Hosp Psychiatry. 2018 Sep - Oct; 2018 May 22. PMID: 30100209.
Electroconvulsive Therapy at a Veterans Health Administration Medical Center.Wilkinson ST, Rosenheck RA. J ECT. 2017 Dec. PMID: 28272097.
Considerations on the Off-label Use of Ketamine as a Treatment for Mood Disorders.Wilkinson ST, Sanacora G. JAMA. 2017 Sep 5. PMID: 28806440.
A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders.Wilkinson ST, Toprak M, Turner MS, Levine SP, Katz RB, Sanacora G. Am J Psychiatry. 2017 Jul 1. PMID: 28669202.
Hippocampal volume changes following electroconvulsive therapy: a systematic review and meta-analysis.Wilkinson ST, Sanacora G, Bloch MH. Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 May; 2017 Feb 5. PMID: 28989984.
Ketamine as a Treatment for Adolescent Depression: A Case Report.Dwyer JB, Beyer C, Wilkinson ST, Ostroff RB, Qayyum Z, Bloch MH. J Am Acad Child Adolesc Psychiatry. 2017 Apr. PMID: 28335880.
Successful Treatment With Electroconvulsive Therapy of a Patient With Bipolar Disorder and a 7-mm Cerebral Aneurysm.Toprak M, Wilkinson ST, Ostroff RB. J ECT. 2017 Mar. PMID: 28072662.
Computer-Assisted Cognitive Behavior Therapy to Prevent Relapse Following Electroconvulsive Therapy.Wilkinson ST, Ostroff RB, Sanacora G. J ECT. 2017 Mar. PMID: 27564424.
Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression.Wilkinson ST, Wright D, Fasula MK, Fenton L, Griepp M, Ostroff RB, Sanacora G. Psychother Psychosom. 2017; 2017 May 11. PMID: 28490030.
Analyzing Patterns of Community Interest at a Legacy Mining Waste Site to Assess and Inform Environmental Health Literacy Efforts.Ramirez-Andreotta MD, Lothrop N, Wilkinson ST, Root RA, Artiola JF, Klimecki W, Loh M. J Environ Stud Sci. 2016 Sep; 2015 Jul 21. PMID: 27595054.
KETAMINE: A POTENTIAL RAPID-ACTING ANTISUICIDAL AGENT?Wilkinson ST, Sanacora G. Depress Anxiety. 2016 Aug; 2016 Apr 15. PMID: 27082101.
A Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications.Wilkinson ST, Radhakrishnan R, D'Souza DC. J Clin Psychiatry. 2016 Aug. PMID: 27561138.
Multimedia exposures to arsenic and lead for children near an inactive mine tailings and smelter site.Loh MM, Sugeng A, Lothrop N, Klimecki W, Cox M, Wilkinson ST, Lu Z, Beamer PI. Environ Res. 2016 Apr; 2016 Jan 21. PMID: 26803211.
The Formation of Marijuana Risk Perception in a Population of Substance Abusing Patients.Wilkinson ST, van Schalkwyk GI, Davidson L, D'Souza DC. Psychiatr Q. 2016 Mar. PMID: 25982082.
Marijuana Legalization: Impact on Physicians and Public Health.Wilkinson ST, Yarnell S, Radhakrishnan R, Ball SA, D'Souza DC. Annu Rev Med. 2016; 2015 Oct 19. PMID: 26515984.
Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder.Wilkinson ST, Stefanovics E, Rosenheck RA. J Clin Psychiatry. 2015 Sep. PMID: 26455669.
Hickam's dictum and the rare convergence of antisynthetase syndrome and hemoglobin SC disease.Wilkinson ST, Grunwald MR, Paik JJ, Ostrow LW, Gelber AC. QJM. 2015 Sep; 2014 Dec 16. PMID: 25519232.
Home Water Treatment Habits and Effectiveness in a Rural Arizona Community.Lothrop N, Wilkinson ST, Verhougstraete M, Sugeng A, Loh MM, Klimecki W, Beamer PI. Water (Basel). 2015. PMID: 26120482.
Electroconvulsive therapy and cerebral aneurysms.Wilkinson ST, Helgeson L, Ostroff RB. J ECT. 2014 Dec. PMID: 25010028.
Medicalization of marijuana--reply.Wilkinson ST, D'Souza DC. JAMA. 2014 Nov 12. PMID: 25387198.
Effects of a hospitalwide pharmacy practice model change on readmission and return to emergency department rates.Anderegg SV, Wilkinson ST, Couldry RJ, Grauer DW, Howser E. Am J Health Syst Pharm. 2014 Sep 1. PMID: 25147171.
Delirium presenting as mania in a patient with end-stage COPD.Wilkinson ST, Chang SB, Foley T, Lipsey JR, MacKinnon DF. Am J Psychiatry. 2014 Aug. PMID: 25082489.
Mitochondria and redox homoeostasis as chemotherapeutic targets.Briehl MM, Tome ME, Wilkinson ST, Jaramillo MC, Lee K. Biochem Soc Trans. 2014 Aug. PMID: 25109983.
Problems with the medicalization of marijuana.Wilkinson ST, D'Souza DC. JAMA. 2014 Jun 18. PMID: 24845238.
Impact of Cannabis Use on the Development of Psychotic Disorders.Wilkinson ST, Radhakrishnan R, D'Souza DC. Curr Addict Rep. 2014 Jun 1. PMID: 25767748.
Preceptor development: providing effective feedback, part 2.Buck B, Wilkinson ST, Phillips H. Hosp Pharm. 2014 Jun. PMID: 24958969.
Gone to Pot - A Review of the Association between Cannabis and Psychosis.Radhakrishnan R, Wilkinson ST, D'Souza DC. Front Psychiatry. 2014; 2014 May 22. PMID: 24904437.
Use of dust fall filters as passive samplers for metal concentrations in air for communities near contaminated mine tailings.Beamer PI, Sugeng AJ, Kelly MD, Lothrop N, Klimecki W, Wilkinson ST, Loh M. Environ Sci Process Impacts. 2014 May. PMID: 24469149.
Reflections on residency: pre-rounding.Wilkinson ST. Yale J Biol Med. 2014 Mar; 2014 Mar 5. PMID: 24600340.
Medical and recreational marijuana: commentary and review of the literature.Wilkinson ST. Mo Med. 2013 Nov-Dec. PMID: 24564006.
Methods to Promote Preceptor Scholarship through Resident Collaboration.Brown JN, Kemp DW, Parker MH, Wilkinson ST. Hosp Pharm. 2013 Sep. PMID: 24421534.
Optimizing the customized residency plan.Phillips H, Wilkinson ST, Buck B. Hosp Pharm. 2013 Jun. PMID: 24421508.
Can the targeted use of a discharge pharmacist significantly decrease 30-day readmissions?Pal A, Babbott S, Wilkinson ST. Hosp Pharm. 2013 May. PMID: 24421494.
Preceptor development: providing effective feedback.Wilkinson ST, Couldry R, Phillips H, Buck B. Hosp Pharm. 2013 Jan. PMID: 24421419.
Leveraging drug-utilization and external benchmarking data to drive change in prescribing behaviors.O'Neal BC, Couldry RJ, Wilkinson ST, Cannella CA, Williams CB, Scott LA, Simpson SQ. Am J Health Syst Pharm. 2012 Nov 1. PMID: 23111677.
Lack and/or aberrant localization of major histocompatibility class II (MHCII) protein in plasmablastic lymphoma.Schmelz M, Montes-Moreno S, Piris M, Wilkinson ST, Rimsza LM. Haematologica. 2012 Oct; 2012 Jun 11. PMID: 22689685.
Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma.Wilkinson ST, Vanpatten KA, Fernandez DR, Brunhoeber P, Garsha KE, Glinsmann-Gibson BJ, Grogan TM, Teruya-Feldstein J, Rimsza LM. Blood. 2012 Feb 9; 2011 Dec 13. PMID: 22167754.
Mitochondrial adaptations to oxidative stress confer resistance to apoptosis in lymphoma cells.Wilkinson ST, Tome ME, Briehl MM. Int J Mol Sci. 2012; 2012 Aug 16. PMID: 22949856.
Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma.Stasik CJ, Nitta H, Zhang W, Mosher CH, Cook JR, Tubbs RR, Unger JM, Brooks TA, Persky DO, Wilkinson ST, Grogan TM, Rimsza LM. Haematologica. 2010 Apr. PMID: 20378577.
Increased cytochrome c correlates with poor survival in aggressive lymphoma.Wilkinson ST, Johnson DB, Tardif HL, Tome ME, Briehl MM. Oncol Lett. 2010 Mar. PMID: 20798784.
Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV.Wilkinson ST, Fernandez DR, Murphy SP, Braziel RM, Campo E, Chan WC, Delabie J, Gascoyne RD, Staudt LM, Jaffe ES, Rosenwald A, Rimsza LM. Leuk Lymphoma. 2009 Nov. PMID: 19814686.
Superoxide dismutase is regulated by LAMMER kinase in Drosophila and human cells.James BP, Staatz WD, Wilkinson ST, Meuillet E, Powis G. Free Radic Biol Med. 2009 Mar 15; 2008 Dec 24. PMID: 19135146.
Mutational analysis of H3 and H4 N termini reveals distinct roles in nuclear import.Blackwell JS Jr, Wilkinson ST, Mosammaparast N, Pemberton LF. J Biol Chem. 2007 Jul 13; 2007 May 15. PMID: 17507373.
Acute renal failure associated with inhaled tobramycin.Cannella CA, Wilkinson ST. Am J Health Syst Pharm. 2006 Oct 1. PMID: 16990632.
Resonant-cavity-enhanced thin-film AlGaAs/GaAs/AlGaAs LED's with metal mirrors.Wilkinson ST, Jokerst NM, Leavitt RP. Appl Opt. 1995 Dec 20. PMID: 21068949.